Skip to main content
Premium Trial:

Request an Annual Quote

Structural Bioinformatics, Boehringer Affiliate Enter AIDS Drug Research Pact

NEW YORK, Dec. 17 — Structural Bioinformatics said on Monday it has formed a research partnership with a Boehringer Ingelheim affiliate in Canada to discover new drug targets against HIV.


According to San Diego-based SBI, the collaboration will allow researchers at Boehringer Ingelheim in Canada to use its database of 3-D protein structures as part of in silico drug-discovery efforts.


SBI's database, called Variome, is a structural pharmacogenomic database with more than 100,000 variant 3-D protein structures for HIV protease and reverse transcriptase. It links nucleotide sequences and structural data with demographic and clinical annotations.


The partnership will allow Boehringer Ingelheim scientists to predict drug activity and prioritize potential compounds, SBI chairman and CEO Edward T. Maggio said in a statement. Researchers will use the database to incorporate information about viral mutations into drug design.


Financial terms of the deal were not disclosed.


Boehringer Ingelheim (Canada) is based in Burlington, Ontario. Its Laval, Quebec pharmaceutical research center, where researchers will use the SBI database, has a focus in virology.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.